Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy

Status Recruiting

Clinical Trial Summary

Myotonic dystrophy is associated with central sleep apnea, excessive daytime sleepiness, diminished working memory, impaired visuospatial skills, and deficits in problem-solving skills. Cerebrospinal fluid (CSF) is a clear, colorless fluid that surrounds and protects the brain. Changes in the composition of CSF can serve as early indicators of changes in brain activity and function. The purpose of this research is to learn about myotonic dystrophy by examining cerebrospinal fluid and brain activity in participants. The tests will be low risk and are well tolerated. The information that we gather from this study may help us evaluate, prevent, diagnose, treat, and improve our understanding of myotonic dystrophy

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06075693
Study type	Observational
Source	Massachusetts General Hospital
Contact	Tamkin Shahraki, MD
Phone	617-726-7506
Email	tshahraki@mgh.harvard.edu
Status	Recruiting
Phase
Start date	August 1, 2022
Completion date	August 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00082108` - Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Enrolling by invitation	`NCT05916677` - Virtual Reality-training in Theory of Mind in the Childhood Form of Myotonic Dystrophy Type 1	N/A
Completed	`NCT02308657` - Multicenter Observational Study of Myotonic Dystrophy Type 1	N/A
Enrolling by invitation	`NCT06316778` - Pelvic Floor Muscle Training for Women With Myotonic Dystrophy	N/A
Completed	`NCT02312011` - A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1	Phase 1/Phase 2
Recruiting	`NCT02269865` - Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy	N/A
Completed	`NCT00577577` - Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1	Phase 2
Completed	`NCT02831504` - PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study)
Completed	`NCT02118779` - Observational Prolonged Trial in Myotonic Dystrophy Type 1	N/A